| Company/Division name | Fore Biotherapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Israel |
| City reshored to: | Philedelphia |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | functional genomics cancer screening |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Skilled workforce availability/training |
